Observational studyBMC cancer2025

Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study.

Jiaxuan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.